Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 08 2020 - 04:01PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities with a primary focus on pruritus by selectively targeting
peripheral kappa opioid receptors, today announced a Company
presentation at the 38th Annual J.P. Morgan Healthcare Conference
on Wednesday, January 15, 2020 at 5:00 p.m. PT (8:00 p.m. ET) in
San Francisco, CA.
A live webcast of the presentation can be
accessed under "Events & Presentations" in the News &
Investors section of the Company's website
at www.CaraTherapeutics.com. An archived webcast recording
will be available on the Cara website for approximately 30
days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that
targets KORs located in the peripheral nervous system, and on
immune cells. In a Phase 3 and two Phase 2 trials, KORSUVA
(CR845/difelikefalin) Injection has demonstrated statistically
significant reductions in itch intensity and concomitant
improvement in pruritus-related quality of life measures in
hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP), and is currently being
investigated in Phase 3 trials in hemodialysis patients with
CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of
pruritus in patients with chronic kidney disease, atopic
dermatitis, and primary biliary cholangitis.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:Jane
UrheimStern Investor Relations, Inc. 212-362-1200
jane.urheim@SternIR.com
MEDIA CONTACT:Annie Starr6
Degrees973-415-8838 astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2023 to Mar 2024